These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 39301694)

  • 1. Non-mitogenic FGF19 mRNA-based therapy for the treatment of experimental metabolic dysfunction-associated steatotic liver disease (MASLD).
    Lopez-Pascual A; Russo-Cabrera JS; Ardaiz N; Palmer T; Graham AR; Uriarte I; Gomar C; Ruiz-Guillamon D; Latasa MU; Arechederra M; Fontanellas A; Monte MJ; Marin JJG; Berasain C; Del Rio CL; Fernandez-Barrena MG; Martini PGV; Schultz JR; Berraondo P; Avila MA
    Clin Sci (Lond); 2024 Oct; 138(20):1265-1284. PubMed ID: 39301694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement of MASLD and MASH by suppression of hepatic N-acetyltransferase 10.
    Yang Y; Lu J; Liu Y; Zhang N; Luo Y; Ma M; Dong Z; Zhang S; Zheng MH; Ruan CC; Wan X; Hu C; Lu Y; Ma X; Zhou B
    Mol Metab; 2024 Nov; 89():102030. PubMed ID: 39293565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblast growth factor 21 is a hepatokine involved in MASLD progression.
    Gallego-Durán R; Ampuero J; Maya-Miles D; Pastor-Ramírez H; Montero-Vallejo R; Rivera-Esteban J; Álvarez-Amor L; Pareja MJ; Rico MC; Millán R; Robles-Frías MJ; Aller R; Rojas Á; Muñoz-Hernández R; Gil-Gómez A; Gato S; García-Lozano M; Arias-Loste MT; Abad J; Calleja JL; Andrade RJ; Crespo J; González-Rodríguez Á; García-Monzón C; Andreola F; Pericás JM; Jalan R; Martín-Bermudo F; Romero-Gómez M
    United European Gastroenterol J; 2024 Oct; 12(8):1056-1068. PubMed ID: 38894596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic Ablation of STE20-Type Kinase MST4 Does Not Alleviate Diet-Induced MASLD Susceptibility in Mice.
    Caputo M; Andersson E; Xia Y; Hou W; Cansby E; Erikson M; Lind DE; Hallberg B; Amrutkar M; Mahlapuu M
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probiotic Mixture Ameliorates a Diet-Induced MASLD/MASH Murine Model through the Regulation of Hepatic Lipid Metabolism and the Gut Microbiome.
    Zhang F; Lo EKK; Chen J; Wang K; Felicianna ; Ismaiah MJ; Leung HKM; Zhao D; Lee JC; El-Nezami H
    J Agric Food Chem; 2024 Apr; 72(15):8536-8549. PubMed ID: 38575146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice.
    Cuño-Gómiz C; de Gregorio E; Tutusaus A; Rider P; Andrés-Sánchez N; Colell A; Morales A; Marí M
    Biol Sex Differ; 2023 Nov; 14(1):85. PubMed ID: 37964320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of ATGL alleviates MASH via impaired PPARα signalling that favours hydrophilic bile acid composition in mice.
    Dixon ED; Claudel T; Nardo AD; Riva A; Fuchs C; Mlitz V; Busslinger G; Schnarnagl H; Stojakovic T; Senéca J; Hinteregger H; Grabner GF; Kratky D; Verkade H; Zimmermann R; Haemmerle G; Trauner M
    J Hepatol; 2024 Sep; ():. PubMed ID: 39357546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Choline-deficient, high-fat diet-induced MASH in Göttingen Minipigs: characterization and effects of a chow reversal period.
    Hvid H; Hjuler ST; Bedossa P; Tiniakos DG; Kamzolas I; Harder LM; Xue Y; Perfield JW; Kirk RK; Latta M; Mikkelsen LF; Pedersen HD;
    Am J Physiol Gastrointest Liver Physiol; 2024 Oct; 327(4):G571-G585. PubMed ID: 39041677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective Effects of Hepatocyte Stress Defenders, Nrf1 and Nrf2, against MASLD Progression.
    Akl MG; Li L; Widenmaier SB
    Int J Mol Sci; 2024 Jul; 25(15):. PubMed ID: 39125617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The adiponectin-derived peptide ALY688 protects against the development of metabolic dysfunction-associated steatohepatitis.
    Huang Z; Sung HK; Yan X; He S; Jin L; Wang Q; Wu X; Hsu HH; Pignalosa A; Crawford K; Sweeney G; Xu A
    Clin Transl Sci; 2024 Jun; 17(6):e13760. PubMed ID: 38847320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased hepatic putrescine levels as a new potential factor related to the progression of metabolic dysfunction-associated steatotic liver disease.
    Núñez-Sánchez MÁ; Martínez-Sánchez MA; Sierra-Cruz M; Lambertos A; Rico-Chazarra S; Oliva-Bolarín A; Balaguer-Román A; Yuste JE; Martínez CM; Mika A; Frutos MD; Llamoza-Torres CJ; Córdoba-Chacón J; Ramos-Molina B
    J Pathol; 2024 Sep; 264(1):101-111. PubMed ID: 39022853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A male mouse model for metabolic dysfunction-associated steatotic liver disease and hepatocellular carcinoma.
    Jeong BK; Choi WI; Choi W; Moon J; Lee WH; Choi C; Choi IY; Lee SH; Kim JK; Ju YS; Kim P; Moon YA; Park JY; Kim H
    Nat Commun; 2024 Aug; 15(1):6506. PubMed ID: 39090079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dysregulated FXR-FGF19 signaling and choline metabolism are associated with gut dysbiosis and hyperplasia in a novel pig model of pediatric NASH.
    Hernandez GV; Smith VA; Melnyk M; Burd MA; Sprayberry KA; Edwards MS; Peterson DG; Bennet DC; Fanter RK; Columbus DA; Steibel JP; Glanz H; Immoos C; Rice MS; Santiago-Rodriguez TM; Blank J; VanderKelen JJ; Kitts CL; Piccolo BD; La Frano MR; Burrin DG; Maj M; Manjarin R
    Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G582-G609. PubMed ID: 32003601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intestinal BMP-9 locally upregulates FGF19 and is down-regulated in obese patients with diabetes.
    Drexler S; Cai C; Hartmann AL; Moch D; Gaitantzi H; Ney T; Kraemer M; Chu Y; Zheng Y; Rahbari M; Treffs A; Reiser A; Lenoir B; Valous NA; Jäger D; Birgin E; Sawant TA; Li Q; Xu K; Dong L; Otto M; Itzel T; Teufel A; Gretz N; Hawinkels LJAC; Sánchez A; Herrera B; Schubert R; Moshage H; Reissfelder C; Ebert MPA; Rahbari NN; Breitkopf-Heinlein K
    Mol Cell Endocrinol; 2023 Jun; 570():111934. PubMed ID: 37085108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15.
    Zhou M; Luo J; Chen M; Yang H; Learned RM; DePaoli AM; Tian H; Ling L
    J Hepatol; 2017 Jun; 66(6):1182-1192. PubMed ID: 28189755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The potential role of omentin-1 in obesity-related metabolic dysfunction-associated steatotic liver disease: evidence from translational studies.
    Salvoza N; Giraudi P; Gazzin S; Bonazza D; Palmisano S; de Manzini N; Zanconati F; Raseni A; Sirianni F; Tiribelli C; Rosso N
    J Transl Med; 2023 Dec; 21(1):906. PubMed ID: 38082368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel fatty acid mimetic with pan-PPAR partial agonist activity inhibits diet-induced obesity and metabolic dysfunction-associated steatotic liver disease.
    Sahin C; Melanson JR; Le Billan F; Magomedova L; Ferreira TAM; Oliveira AS; Pollock-Tahari E; Saikali MF; Cash SB; Woo M; Romeiro LAS; Cummins CL
    Mol Metab; 2024 Jul; 85():101958. PubMed ID: 38763495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases.
    Sandireddy R; Sakthivel S; Gupta P; Behari J; Tripathi M; Singh BK
    Front Cell Dev Biol; 2024; 12():1433857. PubMed ID: 39086662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The anti-obesity effect of FGF19 does not require UCP1-dependent thermogenesis.
    Antonellis PJ; Droz BA; Cosgrove R; O'Farrell LS; Coskun T; Perfield JW; Bauer S; Wade M; Chouinard TE; Brozinick JT; Adams AC; Samms RJ
    Mol Metab; 2019 Dec; 30():131-139. PubMed ID: 31767164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ablation of IFNγ in myeloid cells suppresses liver inflammation and fibrogenesis in mice with hepatic small heterodimer partner (SHP) deletion.
    Zhu L; Litts B; Wang Y; Rein JA; Atzrodt CL; Chinnarasu S; An J; Thorson AS; Xu Y; Stafford JM
    Mol Metab; 2024 May; 83():101932. PubMed ID: 38589002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.